The Filing Desk

IDEAYA Biosciences vs Stoke Therapeutics

IDEAYA Biosciences IDYA · Stoke Therapeutics STOK · Pharmaceuticals

IDEAYA Biosciences reported revenue of $219 million in fiscal 2025, 1.2 times Stoke Therapeutics' $184 million in fiscal 2025. IDEAYA Biosciences' revenue grew 3024.4% in its latest year, and Stoke Therapeutics' grew 404.5%. IDEAYA Biosciences had an operating margin of -72.8%, against -11.2% at Stoke Therapeutics. Free cash flow was −$73 million at IDEAYA Biosciences and $45 million at Stoke Therapeutics.

Side by side

IDEAYA BiosciencesStoke Therapeutics
Latest fiscal yearFY2025, Dec 31, 2025FY2025, Dec 31, 2025
Revenue$219M$184M
Revenue growth3,024.4%404.5%
Revenue growth a year, last 5 years62.2%—
Gross margin——
Operating margin−72.8%−11.2%
Net margin−52.0%−3.7%
Free cash flow−$73M$45M
Free cash flow margin−33.6%24.4%
Return on capital——
Net debt to EBITDA——
Dividends and buybacks$0M$0M
Change in diluted share count8.3%9.7%
Last close$31.83$26.68
P/E at the last close——
Insider trades, last 12 monthsbought $1.6 million, sold $382,096sold $8.7 million
Piotroski F-score——
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.

Ten years

Revenue
US$ billions, fiscal years
IDEAYA BiosciencesStoke Therapeutics
Operating margin
Percent of revenue
IDEAYA BiosciencesStoke Therapeutics
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
IDEAYA BiosciencesStoke Therapeutics

Start a new comparison

Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the IDEAYA Biosciences and Stoke Therapeutics pages.